Network pharmacology-based prediction and “gut microbiota-inflammation-brain axis” validation of the active ingredients and potential mechanisms of Plantagins Herba for treating diabetes-related cognitive dysfunction

BackgroundDiabetes-related cognitive dysfunction (DRCD) is increasingly recognized as a common complication. However, there are currently no specific remedies for DRCD. Plantagins Herba contains many active ingredients that can regulate blood lipids and blood glucose. It is used to treat cognitive i...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhixuan Huang, Jian Liu, Hui Li, Yangwen Ai, Dongyue Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1601689/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850115254568091648
author Zhixuan Huang
Zhixuan Huang
Jian Liu
Jian Liu
Hui Li
Hui Li
Hui Li
Yangwen Ai
Yangwen Ai
Dongyue Zhou
Dongyue Zhou
author_facet Zhixuan Huang
Zhixuan Huang
Jian Liu
Jian Liu
Hui Li
Hui Li
Hui Li
Yangwen Ai
Yangwen Ai
Dongyue Zhou
Dongyue Zhou
author_sort Zhixuan Huang
collection DOAJ
description BackgroundDiabetes-related cognitive dysfunction (DRCD) is increasingly recognized as a common complication. However, there are currently no specific remedies for DRCD. Plantagins Herba contains many active ingredients that can regulate blood lipids and blood glucose. It is used to treat cognitive impairment, but its therapeutic effects and molecular mechanisms on DRCD have not been reported.PurposeTo study the bioactive components, potential targets and molecular mechanisms of Plantagins Herba in the treatment of DRCD.MethodsNetwork pharmacology was applied to predict the active component of Plantagins Herba and the therapeutic targets of diabetes-related cognitive impairment. The molecular docking of the core components with the key targets was verified. Cell and animal models were established, and the mechanism by which hispidulin treats DRCD was explored via flow cytometry, Western blotting, behavioral experiments, HE staining, immunofluorescence, 16S rRNA and other techniques.ResultsBased on the network pharmacology analysis, hispidulin derived from Plantaginis Herba was identified as a promising candidate for further investigation. The computational predictions suggest that the MAPK and PI3K/AKT signaling pathways may play pivotal roles in DRCD pathogenesis. In vitro, Hispidulin reduced inflammation and apoptosis in BV2 cells. It also improved the viability of HT22 cells under inflammation conditions and increased the expression levels of β-catenin and Cyclin D1 proteins. In vivo, hispidulin significantly reduced glucose and lipid metabolism disorders and the abundance of harmful flora in diabetic mice with cognitive impairment. The immunofluorescence results suggested that hispidulin reduced the activation of microglia in the mouse brain and decreased inflammation. The expression of p38MAPK/PI3K/AKT signaling pathway and β-catenin, Cyclin D1 protein, which confirmed regulatory effect of Hispidulin in hippocampal tissue.ConclusionHispidulin ameliorated disease manifestations in a DRCD-induced murine model, attenuating neuroinflammation and histopathological damage in hippocampal tissues through gut microbiota modulation.
format Article
id doaj-art-0c4b301a4fa240cf84ba69704d9bb93c
institution OA Journals
issn 1663-9812
language English
publishDate 2025-06-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj-art-0c4b301a4fa240cf84ba69704d9bb93c2025-08-20T02:36:38ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-06-011610.3389/fphar.2025.16016891601689Network pharmacology-based prediction and “gut microbiota-inflammation-brain axis” validation of the active ingredients and potential mechanisms of Plantagins Herba for treating diabetes-related cognitive dysfunctionZhixuan Huang0Zhixuan Huang1Jian Liu2Jian Liu3Hui Li4Hui Li5Hui Li6Yangwen Ai7Yangwen Ai8Dongyue Zhou9Dongyue Zhou10Jiangxi Province Key Laboratory of Traditional Chinese Medicine Pharmacology, Institute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences, Nanchang, ChinaJiangxi Health Industry Institute of Traditional Chinese Medicine, Nanchang, ChinaJiangxi Province Key Laboratory of Traditional Chinese Medicine Pharmacology, Institute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences, Nanchang, ChinaJiangxi Health Industry Institute of Traditional Chinese Medicine, Nanchang, ChinaJiangxi Province Key Laboratory of Traditional Chinese Medicine Pharmacology, Institute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences, Nanchang, ChinaJiangxi Health Industry Institute of Traditional Chinese Medicine, Nanchang, ChinaInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, ChinaJiangxi Province Key Laboratory of Traditional Chinese Medicine Pharmacology, Institute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences, Nanchang, ChinaJiangxi Health Industry Institute of Traditional Chinese Medicine, Nanchang, ChinaJiangxi Province Key Laboratory of Traditional Chinese Medicine Pharmacology, Institute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences, Nanchang, ChinaJiangxi Health Industry Institute of Traditional Chinese Medicine, Nanchang, ChinaBackgroundDiabetes-related cognitive dysfunction (DRCD) is increasingly recognized as a common complication. However, there are currently no specific remedies for DRCD. Plantagins Herba contains many active ingredients that can regulate blood lipids and blood glucose. It is used to treat cognitive impairment, but its therapeutic effects and molecular mechanisms on DRCD have not been reported.PurposeTo study the bioactive components, potential targets and molecular mechanisms of Plantagins Herba in the treatment of DRCD.MethodsNetwork pharmacology was applied to predict the active component of Plantagins Herba and the therapeutic targets of diabetes-related cognitive impairment. The molecular docking of the core components with the key targets was verified. Cell and animal models were established, and the mechanism by which hispidulin treats DRCD was explored via flow cytometry, Western blotting, behavioral experiments, HE staining, immunofluorescence, 16S rRNA and other techniques.ResultsBased on the network pharmacology analysis, hispidulin derived from Plantaginis Herba was identified as a promising candidate for further investigation. The computational predictions suggest that the MAPK and PI3K/AKT signaling pathways may play pivotal roles in DRCD pathogenesis. In vitro, Hispidulin reduced inflammation and apoptosis in BV2 cells. It also improved the viability of HT22 cells under inflammation conditions and increased the expression levels of β-catenin and Cyclin D1 proteins. In vivo, hispidulin significantly reduced glucose and lipid metabolism disorders and the abundance of harmful flora in diabetic mice with cognitive impairment. The immunofluorescence results suggested that hispidulin reduced the activation of microglia in the mouse brain and decreased inflammation. The expression of p38MAPK/PI3K/AKT signaling pathway and β-catenin, Cyclin D1 protein, which confirmed regulatory effect of Hispidulin in hippocampal tissue.ConclusionHispidulin ameliorated disease manifestations in a DRCD-induced murine model, attenuating neuroinflammation and histopathological damage in hippocampal tissues through gut microbiota modulation.https://www.frontiersin.org/articles/10.3389/fphar.2025.1601689/fullPlantagins HerbaHispidulinnetwork pharmacologydiabetes-related cognitive dysfunction“gut microbiota-inflammation-brain axis”
spellingShingle Zhixuan Huang
Zhixuan Huang
Jian Liu
Jian Liu
Hui Li
Hui Li
Hui Li
Yangwen Ai
Yangwen Ai
Dongyue Zhou
Dongyue Zhou
Network pharmacology-based prediction and “gut microbiota-inflammation-brain axis” validation of the active ingredients and potential mechanisms of Plantagins Herba for treating diabetes-related cognitive dysfunction
Frontiers in Pharmacology
Plantagins Herba
Hispidulin
network pharmacology
diabetes-related cognitive dysfunction
“gut microbiota-inflammation-brain axis”
title Network pharmacology-based prediction and “gut microbiota-inflammation-brain axis” validation of the active ingredients and potential mechanisms of Plantagins Herba for treating diabetes-related cognitive dysfunction
title_full Network pharmacology-based prediction and “gut microbiota-inflammation-brain axis” validation of the active ingredients and potential mechanisms of Plantagins Herba for treating diabetes-related cognitive dysfunction
title_fullStr Network pharmacology-based prediction and “gut microbiota-inflammation-brain axis” validation of the active ingredients and potential mechanisms of Plantagins Herba for treating diabetes-related cognitive dysfunction
title_full_unstemmed Network pharmacology-based prediction and “gut microbiota-inflammation-brain axis” validation of the active ingredients and potential mechanisms of Plantagins Herba for treating diabetes-related cognitive dysfunction
title_short Network pharmacology-based prediction and “gut microbiota-inflammation-brain axis” validation of the active ingredients and potential mechanisms of Plantagins Herba for treating diabetes-related cognitive dysfunction
title_sort network pharmacology based prediction and gut microbiota inflammation brain axis validation of the active ingredients and potential mechanisms of plantagins herba for treating diabetes related cognitive dysfunction
topic Plantagins Herba
Hispidulin
network pharmacology
diabetes-related cognitive dysfunction
“gut microbiota-inflammation-brain axis”
url https://www.frontiersin.org/articles/10.3389/fphar.2025.1601689/full
work_keys_str_mv AT zhixuanhuang networkpharmacologybasedpredictionandgutmicrobiotainflammationbrainaxisvalidationoftheactiveingredientsandpotentialmechanismsofplantaginsherbafortreatingdiabetesrelatedcognitivedysfunction
AT zhixuanhuang networkpharmacologybasedpredictionandgutmicrobiotainflammationbrainaxisvalidationoftheactiveingredientsandpotentialmechanismsofplantaginsherbafortreatingdiabetesrelatedcognitivedysfunction
AT jianliu networkpharmacologybasedpredictionandgutmicrobiotainflammationbrainaxisvalidationoftheactiveingredientsandpotentialmechanismsofplantaginsherbafortreatingdiabetesrelatedcognitivedysfunction
AT jianliu networkpharmacologybasedpredictionandgutmicrobiotainflammationbrainaxisvalidationoftheactiveingredientsandpotentialmechanismsofplantaginsherbafortreatingdiabetesrelatedcognitivedysfunction
AT huili networkpharmacologybasedpredictionandgutmicrobiotainflammationbrainaxisvalidationoftheactiveingredientsandpotentialmechanismsofplantaginsherbafortreatingdiabetesrelatedcognitivedysfunction
AT huili networkpharmacologybasedpredictionandgutmicrobiotainflammationbrainaxisvalidationoftheactiveingredientsandpotentialmechanismsofplantaginsherbafortreatingdiabetesrelatedcognitivedysfunction
AT huili networkpharmacologybasedpredictionandgutmicrobiotainflammationbrainaxisvalidationoftheactiveingredientsandpotentialmechanismsofplantaginsherbafortreatingdiabetesrelatedcognitivedysfunction
AT yangwenai networkpharmacologybasedpredictionandgutmicrobiotainflammationbrainaxisvalidationoftheactiveingredientsandpotentialmechanismsofplantaginsherbafortreatingdiabetesrelatedcognitivedysfunction
AT yangwenai networkpharmacologybasedpredictionandgutmicrobiotainflammationbrainaxisvalidationoftheactiveingredientsandpotentialmechanismsofplantaginsherbafortreatingdiabetesrelatedcognitivedysfunction
AT dongyuezhou networkpharmacologybasedpredictionandgutmicrobiotainflammationbrainaxisvalidationoftheactiveingredientsandpotentialmechanismsofplantaginsherbafortreatingdiabetesrelatedcognitivedysfunction
AT dongyuezhou networkpharmacologybasedpredictionandgutmicrobiotainflammationbrainaxisvalidationoftheactiveingredientsandpotentialmechanismsofplantaginsherbafortreatingdiabetesrelatedcognitivedysfunction